3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Neoplasms
2
Mesothelioma
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Ovarian Neoplasms
1
Medical Oncology
1
Lung Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
39
Cisplatin
24
Oxaliplatin
15
pembrolizumab
12
Capecitabine
12
Fluorouracil
9
Leucovorin
7
Albumin-Bound Paclitaxel
7
lenvatinib
6
Radiofrequency Ablation
6
Panitumumab
6
130-nm albumin-bound paclitaxel
6
Irinotecan
5
Bevacizumab
5
durvalumab
4
Taxes
4
Nivolumab
4
Hepatectomy
4
Drug Therapy
4
tremelimumab
3
apatinib
3
Radiosurgery
3
Platinum
3
Injections
3
Floxuridine
3
Cetuximab
3
1,2-diaminocyclohexaneplatinum II citrate
3
trametinib
2
spartalizumab
2
sintilimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cholangiocarcinoma
×
anetumab ravtansine
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled